NCT02038842View on ClinicalTrials.gov

Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates in Healthy Volunteers

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

October 31, 2015

Study Completion Date

March 31, 2016

Conditions
HIV Infection
Interventions
BIOLOGICAL

LIPO-5

LIPO-5: 1mL IntraMuscular, 2 shots;

BIOLOGICAL

MVA HIV-B (MVATG17401)

MVA HIV-B (MVATG17401): 0.5mL IntraMuscular, 2 shots;

BIOLOGICAL

GTU®-MultiHIV B: 0.5 mL IM via Biojector® 2000 and 0.5mL IntraDermic, 3 shots

GTU®-MultiHIV B: 0.5 mL IM via Biojector® 2000 and 0.5mL IntraDermic, 3 shots

Trial Locations (1)

94010

Service d'Immunologie Clinique 51, avenue du Marechal de Lattre de Tassigny, Créteil

All Listed Sponsors
lead

ANRS, Emerging Infectious Diseases

OTHER_GOV

NCT02038842 - Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates in Healthy Volunteers | Biotech Hunter | Biotech Hunter